Swissmedic approves Basilea's antibiotic Zevtera(r)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Swissmedic approves Basilea's antibiotic Zevtera(r) (ceftobiprole medocaril) for the treatment of pneumonia

BASEL, Switzerland, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that the Swiss regulatory authority Swissmedic has approved the antibiotic Zevtera ® (ceftobiprole medocaril) for the treatment in adults of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). The license will be issued by Swissmedic following formal publication of the Product Information. Ceftobiprole for the treatment of pneumonia has already been approved in twelve other European countries. 1

Each year, approximately 70,000 hospital-acquired infections occur in Switzerland, leading to the death of about 2,000 patients, according to Swissnoso, a Swiss infectious diseases and hospital hygiene expert group. 2 HAP is among the most common of these hospital-acquired infections. 3

Ceftobiprole is a new-generation broad-spectrum cephalosporin antibiotic with rapid bactericidal activity against Gram-positive and Gram-negative bacteria associated with pneumonia, including methicillin-resistant Staphylococcus aureus (MRSA) and susceptible strains of Pseudomonas spp. 4 Ceftobiprole is administered intravenously and is the active moiety of the prodrug ceftobiprole medocaril.

Ronald Scott, Chief Executive Officer of Basilea, commented: "We are very pleased that Swissmedic has approved Zevtera for the treatment of pneumonia in Switzerland. Antibiotic-resistant infections are a major healthcare threat. The development of new antibiotics is part of Basilea's commitment to combat drug resistance."

Prof. Achim Kaufhold, Chief Medical Officer of Basilea, added: "The approval of ceftobiprole in Switzerland offers a new treatment option for physicians and their patients to support the treatment of pneumonia, when empiric therapy requires broad-spectrum activity against frequent Gram-positive and Gram-negative pathogens."

About pneumonia

Pneumonia is a common infection 5, 6 and is generally classified according to the location of the patient when the infection is contracted, since this has a major bearing on the likely type of pathogen causing the disease, the treatment and the patient's prognosis. Common infection types are community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). CAP is defined as pneumonia acquired outside hospital or extended-care facilities or occurring less than 48 hours after hospital admission. 7 HAP is pneumonia that occurs 48 hours or more after admission to hospital and did not appear to be incubating at the time of admission. HAP is one of the most common infectious diseases acquired in hospitals, affecting 0.5-1.7% of hospitalized patients. 3 The reported all-cause mortality rate for HAP varies widely, ranging from 20-70%. 8, 9 HAP is caused by a wide spectrum of Gram-positive bacteria such as Staphylococcus aureus , particularly MRSA, and Gram-negative bacteria. Community-acquired pneumonia is a common condition with up to 60% of the patients requiring hospital admission and intravenous antibiotics. 10 Prompt empiric intervention with an appropriate broad-spectrum antibiotic treatment is accepted as best medical practice. 11 The increasing incidence of bacteria resistant to many established antibiotics is a major concern.

About MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is a Gram-positive bacterium which is an important cause of pneumonia, accounting for 20-40% of all HAP cases. 12 MRSA rates are above 25% in seven of the 30 countries of the European Union (EU) and the European Economic Area reporting to the European Centre for Disease Prevention and Control (ECDC). Based on these figures and generally high MRSA rates, the ECDC considers MRSA to be a public health priority. 13 The ECDC estimates that approximately 4 million patients acquire a healthcare-associated infection in the EU every year, resulting in at least 37,000 deaths, of which 25,000 are currently estimated to be due to the most common resistant bacteria, including Staphylococcus aureus and Pseudomonas aeruginosa . 14

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to develop and commercialize innovative pharmaceutical products to meet the significant medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com .

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Media Relations Investor Relations
Peer Nils Schröder, PhD
Head Public Relations &
Corporate Communications
+41 61 606 1102
media_relations@basilea.com
Barbara Zink, PhD, MBA
Head Corporate Development

+41 61 606 1233
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com .

References

1 Following approval under the European decentralized procedure, ceftobiprole has received national licenses for the treatment of CAP and HAP (excluding VAP) in adults in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Norway, Spain, Sweden and the United Kingdom; reimbursement and pricing authorization in several countries including Spain is ongoing
2 Swiss Federal Office of Public Health (FOPH). 2014. 140314_FAQ_Antibiotikaresistenzen_d_updateIB.pdf. Retrieved from http://www.bag.admin.ch/themen/medizin/14226/...ml?lang=de [Accessed August 18, 2014]
3 R. Masterton et al. Hospital-acquired pneumonia guidelines in Europe: a review of their status and future development. Journal of Antimicrobial Chemotherapy 2007 (60), 206-213
4 Y. Y. Syed. Ceftobiprole medocaril: A review of its use in patients with hospital- or community-acquired pneumonia. Drugs 2014 (74), 1523-1542
5 M. R. Loebinger, R. Wilson. Pneumonia. Medicine 2012 (40), 329-334
6 White Book. http://www.erswhitebook.org/chapters/acute-lo...pneumonia/ [Accessed September 30, 2014]
7 G. B. Nair, M. S. Niederman. Community-acquired pneumonia: an unfinished battle. Medical Clinics of North America 2011 (95), 1143-1161
8 American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Journal of Respiratory and Critical Care Medicine 2005 (171), 388-416
9 M. H. Kollef et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005 (128), 3854-3862
10 W. I. Sligl et al. Severe community-acquired pneumonia. Critical Care Clinics 2013 (29), 563-601
11 G. Höffken et al. Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany. Pneumologie 2009 (63), e1-e68
12 E. Rubinstein et al. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clinical Infectious Diseases 2008 (46), Suppl 5, S378-S385
13 European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC 2013
14 European Centre for Disease Prevention and Control. Antimicrobial resistance and healthcare-associated infections. http://www.ecdc.europa.eu/en/activities/disea...ramme.aspx [Accessed November 28, 2014]

Press release (PDF) http://hugin.info/134390/R/1882292/664055.pdf

HUG#1882292

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 199

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 244

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 47

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 129

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 63

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 266

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Banco Comercial Português Highlights Positive Share Buy-Back Activities

Updated Category News Views 137

Banco Comercial Português: An Overview of Recent Developments Banco Comercial Português, S.A., recognized for its pivotal role in the financial sector, has recently shared insights about its Share Buy-Back Programme. This initiative reflects the bank's commitment to enhancing shareholder value while solidifying its market presence. The interim report detailing the...

Continue Reading
How a $1000 Investment in Texas Instruments Transforms Over 15 Years

Updated Category News Views 135

Understanding the Growth of Texas Instruments Investments Texas Instruments (NASDAQ: TXN) has displayed impressive growth over the past 15 years, outpacing the market by an average of 2.3% annually. This translates to a robust average annual return of 14.17%, reflecting this company's strong position in the semiconductor industry. With a market capitalization now standing...

Continue Reading
Bitdeer Technologies Group's Q4 2024 Financial Overview

Updated Category News Views 204

Bitdeer Technologies Group's Financial Results Analysis Bitdeer Technologies Group (NASDAQ: BTDR), a prominent player in blockchain technology and high-performance computing, has recently unveiled its unaudited financial results for the final quarter of 2024. The announcement sheds light on the company's performance, revealing significant shifts in revenue and expenses...

Continue Reading
NodeAI Revolutionizes Lung Cancer Care with AI Solutions

Updated Category News Views 206

NodeAI's Groundbreaking Achievement in Cancer Diagnostics NodeAI, a pioneering startup based in Hamilton, Ontario, has recently garnered attention for its exceptional advancements in lung cancer diagnostics. The company participated in FACIT's annual pitch competition, known as Falcons' Fortunes, and emerged victorious, earning a prestigious award for its innovative...

Continue Reading
Runway Growth Capital Bolsters Leadership with Rovner

Updated Category News Views 72

A New Era for Runway Growth Capital Alright folks, here's the scoop for anyone tracking the moves in the growth lending space: Michael Rovner, with his hefty 30-year career in the financial sector, is now taking on the role of Co-Chief Executive Officer and Co-Chief Investment Officer at Runway Growth Capital. This guy's a veteran, no doubt, having navigated the overlaps...

Continue Reading